Carvedilol can prevent cardiac events in duchenne muscular dystrophy

Internal Medicine

Volumn 49, Issue 14, 2010, Pages 1357-1363

  Matsumura, Tsuyoshi ^a   Tamura, Takuhisa ^b   Kuru, Satoshi ^c   Kikuchi, Yasuki ^d   Kawai, Mitsuru ^b  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

^b Higashisaitama National Hospital   (Japan)

^c SUZUKA NATIONAL HOSPITAL   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Beta blocker; Cardiac dysfunction; Cardioprotection; Duchenne muscular dystrophy

Indexed keywords

CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PIMOBENDAN;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FAINTNESS; FATIGUE; GENERAL CONDITION DETERIORATION; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEART RATE; HEMODYNAMIC MONITORING; HUMAN; LOW DRUG DOSE; LUNG INFECTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; SIDE EFFECT; SPUTUM; SURVIVAL RATE;

ADOLESCENT; ADULT; CARBAZOLES; CHILD; CHRONIC DISEASE; HEART FAILURE; HUMANS; LONGITUDINAL STUDIES; MUSCULAR DYSTROPHY, DUCHENNE; PROPANOLAMINES; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77954996985     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3259     Document Type: Article

References (32)

1. Gomez-Merino E, Bach JR. Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing. Am J Phys Med Rehabil 81: 411-415, 2002.
2. Tatara K, Shinno S. Management of mechanical ventilation and prognosis in Duchenne muscular dystrophy. Iryo 62: 566-571, 2008.
3. Mori K, Manabe T, Nii M, Hayabuchi Y, Kuroda Y, Tatara K. Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol 23: 160-166, 2002.
4. Demachi J, Kagaya Y, Watanabe J, et al. Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromuscul Disord 14: 732-739, 2004.
5. Matsumura T, Saito T, Fujimura H, Shinno S. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain Dev 29: 496-501, 2007.
6. van Bockel EA, Lind JS, Zijlstra JG, et al. Cardiac assessment of patients with late stage Duchenne muscular dystrophy. Neth Heart J 17: 232-237, 2009.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302, 1991.
8. Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on longterm mortality in severe congestive heart failure. CONSENSUS Trial Group. Am J Cardiol 69: 103-107, 1992.
9. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752, 1997.
10. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587, 2000.
11. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675, 2001.
12. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 759-766, 2003.
13. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342: 1441-1446, 1993.
14. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334: 1349-1355, 1996.
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007, 1999.
16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). A randomized trial. Lancet 353: 9-13, 1999.
17. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658, 2001.
18. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodeling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 18: 57-66, 2004.
19. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147: 324-330, 2004.
20. Tamura T, Shibuya T, Iida M, Ishihara T, Fukunaga H, Kyo S. Clinical evaluation of captopril in chronic cardiac dysfunction in patients with Duchenne muscular dystrophy. Rinsho Iyaku 12: 3635-3646, 1996.
21. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 137: 895-902, 1999.
22. Abraham WT. Beta-blockers: the new standard of therapy for mild heart failure. Arch Intern Med 160: 1237-1247, 2000.
23. Saito T, Matsumura T, Miyai I, Nozaki S, Shinno S. Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku 41: 691-694, 2001.
24. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138: 505-511, 2001.
25. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298: 1171-1179, 2007.
26. Rhodes J, Margossian R, Darras BT, et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 29: 343-351, 2008.
27. Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am J Cardiol 85: 1495-1497; A1497, 2000.
28. Takeda N, Ohtaki E, Misu K, et al. Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status. Intern Med 41: 1147-1152, 2002.
29. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 66: 149-157, 2002.
30. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367, 1989.
31. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. Jama 287: 628-640, 2002.
32. Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 70: 991-994, 2006.